Ascentage Pharma partners with AstraZeneca unit to test combo cancer therapy
Ascentage Pharma inked a collaboration deal with Acerta Pharma, an AstraZeneca unit that focuses on blood cancers, to test their cancer drugs when used as a combination therapy.
The Suzhou-based drug maker will sponsor a clinical trial that will pair its Bcl-2 inhibitor APG-2575 with Acerta's commercialized BTK inhibitor Calquence, otherwise known as acalabrutinib. The open-label, Phase 1b/2 study will assess whether this combination yields favorable efficacy and safety outcomes for patients with a specific type of relapsed or refractory non-Hodgkin lymphoma called chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL.
"Combination therapy is becoming more important in cancer treatment, and the rationale of a Bcl-2 inhibitor combined with a BTK inhibitor is sound. We hope that APG-2575 combined with Calquence will show synergistic effects in the treatment of CLL/SLL," Dajun Yang, Ascentage's chair and CEO, said in a statement.
The Suzhou-based drug maker will sponsor a clinical trial that will pair its Bcl-2 inhibitor APG-2575 with Acerta's commercialized BTK inhibitor Calquence, otherwise known as acalabrutinib. The open-label, Phase 1b/2 study will assess whether this combination yields favorable efficacy and safety outcomes for patients with a specific type of relapsed or refractory non-Hodgkin lymphoma called chronic lymphocytic leukemia/small lymphocytic lymphoma, or CLL/SLL.
"Combination therapy is becoming more important in cancer treatment, and the rationale of a Bcl-2 inhibitor combined with a BTK inhibitor is sound. We hope that APG-2575 combined with Calquence will show synergistic effects in the treatment of CLL/SLL," Dajun Yang, Ascentage's chair and CEO, said in a statement.
.png)
No hay comentarios:
Publicar un comentario